Fact-checked by Grok 2 weeks ago

Hospital Anxiety and Depression Scale

The Hospital Anxiety and Depression Scale (HADS) is a self-report comprising 14 multiple-choice items, with seven assessing anxiety symptoms and seven assessing symptoms, designed specifically to screen for emotional distress in medical patients without relying on somatic symptoms that could overlap with physical illness. Developed by psychiatrists Aaron S. Zigmond and R. Philip Snaith and first published in 1983, the HADS was intended for use in hospital outpatient clinics to help non-psychiatric physicians identify clinically significant anxiety and , enabling timely referral for psychological support. Each item is scored on a 4-point from 0 to 3, yielding subscale totals ranging from 0 to 21, where scores of 8–10 indicate borderline abnormal levels and 11 or higher suggest probable caseness; the tool typically takes 2–5 minutes to complete and is suitable for self-administration. Originally validated in a sample of 100 medical outpatients in the , the HADS demonstrated against clinical interviews, with subsequent evaluations confirming good (Cronbach's alpha typically 0.80–0.83 for the anxiety and subscales, respectively), establishing its reliability as a brief screening instrument in care settings. Subsequent psychometric evaluations have confirmed its utility across diverse populations, including , community samples, adolescents, and the elderly, with translations into over 80 languages and adaptations for various chronic conditions such as cancer, , and . A 2002 review highlighted its widespread adoption, noting more than 600 citations by that time and its role in facilitating the detection of hidden psychiatric morbidity in medical practice. While the HADS remains one of the most frequently used anxiety and screening tools in non-psychiatric medical contexts, recent meta-analyses have examined its diagnostic accuracy, finding that a subscale cutoff of ≥7 optimizes sensitivity (0.82) and specificity (0.78) for detecting major in physically ill patients, though it performs less robustly for anxiety disorders. A 2025 Cochrane assessed the accuracy of the HADS anxiety subscale for detecting anxiety disorders in adults in non-psychiatric medical or community settings. Ongoing continues to refine its , with bifactor models supporting a general distress alongside anxiety and specifics, underscoring its enduring relevance despite debates over unidimensional versus multidimensional interpretations.

Development and Purpose

Historical Background

The Hospital Anxiety and Depression Scale (HADS) was developed in 1983 by psychiatrists A.S. Zigmond and R.P. Snaith at the in the . This self-assessment tool emerged from their work in the Department of at , addressing the challenges of identifying emotional distress in non-psychiatric medical settings. The scale was first published in Acta Psychiatrica Scandinavica, volume 67, issue 6, pages 361–370, under the title "The hospital anxiety and depression scale." It was created in response to the growing recognition of issues among hospital patients in the late , particularly the need for a brief screening instrument that avoided symptoms to distinguish psychological from physical symptoms. This design aimed to facilitate quick detection of anxiety and by staff without requiring specialized psychiatric training. Initial validation occurred in a sample of 100 medical outpatients at in , where the scale demonstrated reliability in identifying states of anxiety and depression within this population. This foundational study established the HADS as a practical tool for clinical use, setting the stage for its widespread adoption in medical settings globally.

Design Rationale

The Hospital Anxiety and Depression Scale (HADS) was developed to identify states of anxiety and depression specifically among physically ill patients in hospital settings, where traditional assessment tools often confound psychological symptoms with complaints common to . By deliberately excluding items related to physical manifestations such as , sleep disturbances, or appetite changes, the scale focuses on cognitive and emotional aspects of distress, enabling clinicians to distinguish issues from physiological ones without misattribution. This design choice addressed limitations in existing instruments, such as the , which incorporated numerous somatic symptoms that could inflate scores in hospitalized patients regardless of their emotional state, rendering them less suitable for non-psychiatric medical environments. The HADS was conceptualized as a brief self-report to fit the demands of busy clinical practices, allowing completion in 2-5 minutes while patients await consultation, thus facilitating efficient screening without requiring extensive training or time from healthcare providers. Initially published in 1983 by Zigmond and Snaith, the scale employed straightforward language and neutral phrasing to minimize cultural or linguistic biases, aiming for broad applicability in diverse patient populations within English-speaking contexts. However, later revealed translation challenges and idiomatic differences that necessitated adaptations for non-Western or multilingual settings to ensure equivalence.

Structure and Content

Questionnaire Items

The Hospital Anxiety and Depression Scale (HADS) consists of 14 self-report items designed to assess symptoms of anxiety and experienced over the past week, each rated on a 4-point ranging from 0 (no symptom) to 3 (severe symptom), with response options tailored to the item's wording to reflect frequency or intensity. The items alternate between anxiety (odd-numbered: 1, 3, 5, 7, 9, 11, 13) and (even-numbered: 2, 4, 6, 8, 10, 12, 14) themes, focusing on emotional rather than symptoms to suit medical settings. Certain positively worded items require reverse scoring (e.g., a response of 0 becomes 3, and vice versa) so that higher scores consistently indicate greater symptom severity across all items.

Anxiety Items

These seven items probe psychological aspects of anxiety, including tension, apprehension, worry, and panic, without referencing physical sensations like heartbeat or dizziness.
  1. I feel tense or “wound up” (response options: 0 = Not at all; 1 = From time to time, occasionally; 2 = A lot of the time; 3 = Most of the time).
  2. I get a sort of frightened feeling as if something awful is about to happen (0 = Not at all; 1 = A little, but it doesn’t worry me; 2 = Yes, but not too badly; 3 = Very definitely and quite badly).
  3. Worrying thoughts go through my mind (0 = Only occasionally; 1 = From time to time, but not too often; 2 = A lot of the time; 3 = A great deal of the time).
  4. I can sit at ease and feel relaxed (reverse-scored: 0 = Definitely; 1 = Usually; 2 = Not often; 3 = Not at all).
  5. I get a sort of frightened feeling like “butterflies” in the stomach (0 = Not at all; 1 = Occasionally; 2 = Quite often; 3 = Very often).
  6. I feel restless as if I have to be on the move (0 = Not at all; 1 = Not very much; 2 = Quite a lot; 3 = Very much indeed).
  7. I get sudden feelings of panic (0 = Not at all; 1 = Not very often; 2 = Quite often; 3 = Very often indeed).

Depression Items

These seven items address core depressive features such as , loss of interest, cheerlessness, and , emphasizing psychological manifestations.
  1. I still enjoy the things I used to enjoy (reverse-scored: 0 = Definitely as much; 1 = Not quite so much; 2 = Only a little; 3 = Hardly at all).
  2. I can laugh and see the funny side of things (reverse-scored: 0 = As much as I always could; 1 = Not quite so much now; 2 = Definitely not so much now; 3 = Not at all).
  3. I feel cheerful (reverse-scored: 0 = Most of the time; 1 = Sometimes; 2 = Not often; 3 = Not at all).
  4. I feel as if I am slowed down (0 = Not at all; 1 = Sometimes; 2 = Very often; 3 = Nearly all the time).
  5. I have lost interest in my appearance (0 = I take just as much care as ever; 1 = I may not take quite as much care; 2 = I don’t take as much care as I should; 3 = Definitely).
  6. I look forward with enjoyment to things (reverse-scored: 0 = As much as I ever did; 1 = Rather less than I used to; 2 = Definitely less than I used to; 3 = Hardly at all).
  7. I can enjoy a good book or radio or TV program (reverse-scored: 0 = Often; 1 = Sometimes; 2 = Not often; 3 = Very seldom).
The items are separated into anxiety and depression subscales for further analysis.

Subscales

The Hospital Anxiety and Depression Scale (HADS) consists of two distinct 7-item subscales designed to assess anxiety and depression separately in medical settings. The HADS-A (anxiety) subscale measures autonomic and subjective aspects of anxiety, such as feelings of tension, restlessness, and worry, with items focusing on psychological rather than physical symptoms to avoid with complaints common in patients. For instance, it includes queries about feeling "tense or wound up" or "worried a lot about something." In contrast, the HADS-D (depression) subscale targets and motivational loss, capturing symptoms like reduced enjoyment in activities, hopelessness, and slowed thinking, while deliberately excluding elements such as changes or disturbances to emphasize emotional rather than physiological manifestations. Examples include items assessing whether the respondent still finds in things they used to enjoy or feels as if they are moving slower than usual. This separation allows for the of anxiety and depression as distinct emotional disorders, facilitating targeted clinical evaluation without overlap from physical health issues. Although a total HADS score can be calculated by summing all 14 items, the subscales are intended for analysis to provide nuanced insights into anxiety and severity. The original design by Zigmond and Snaith assumed orthogonal factors, positing that anxiety and operate as constructs. However, empirical support for this strict has varied, with some studies indicating correlated factors or a dominant general distress component alongside the subscales.

Administration and Scoring

Administration Procedures

The Hospital Anxiety and Depression Scale (HADS) is a self-administered intended for screening anxiety and in clinical or research settings with medical patients. It is typically distributed to individuals in waiting rooms, clinics, or at bedside, with no need for clinician prompting or supervision during completion to minimize bias and ensure respondent independence. Completion of the HADS requires approximately 2 to 5 minutes, making it practical for busy healthcare environments, and it is suitable for literate adults aged 16 years and older, including older adults up to 90 years or more in normative samples. Patients receive clear instructions to respond based on their feelings over the past week, selecting from a 4-point (ranging from 0 to 3) for each of the 14 items, with an emphasis on immediate, honest responses rather than overthinking. To support global use, the HADS has been translated and culturally adapted into 115 languages, facilitating administration across diverse linguistic and cultural contexts. For patients with low , visual impairments, or cognitive challenges that preclude self-completion, a verbal or interviewer-assisted format can be employed, where a trained professional reads items aloud and records responses to maintain without altering the tool's intent. Prior to administration, ethical protocols require obtaining from participants, clearly communicating the HADS's role as a screening instrument for and case identification rather than a standalone diagnostic measure, to promote and appropriate follow-up .

Scoring Calculations

The Hospital Anxiety and Depression Scale (HADS) consists of 14 self-report items, each rated on a 4-point from 0 to 3, with 0 indicating no presence of the symptom and 3 indicating severe presence of the symptom. The response options for each item are tailored to its wording, ensuring that higher scores consistently reflect greater psychological distress; for positively worded items, the scale labels are reversed accordingly—for instance, item 2 on the depression subscale ("I still enjoy the things I used to enjoy") is scored as 0 for "Definitely as much," 1 for "Not quite so much," 2 for "Only very little," and 3 for "Hardly at all." Subscale scores are computed by summing the relevant items after assigning the 0–3 values. The anxiety subscale score (HADS-A) is the sum of seven anxiety items (1, 3, 5, 7, 9, 11, and 13), yielding a range of 0–21. The depression subscale score (HADS-D) is the sum of the seven depression items (2, 4, 6, 8, 10, 12, and 14), also ranging from 0–21. The total HADS score is the sum of HADS-A and HADS-D, with a possible range of 0–42. A representative formula for calculating the HADS-A score is: \text{HADS-A} = \text{Item 1} + \text{Item 3} + \text{Item 5} + \text{Item 7} + \text{Item 9} + \text{Item 11} + \text{Item 13} where each item contributes a value between 0 and 3. An analogous summation applies to the HADS-D. For handling , responses with more than 20% unanswered items (more than about 3 out of 14) should be discarded to maintain score validity. When fewer items are missing, subscale scores can be pro-rated by computing the of the completed items in that subscale and multiplying by 7, provided at least half the subscale items (4 out of 7) are answered; alternatively, simple imputation using the subscale of completed items is recommended for individual-level scoring.

Interpretation and Caseness

Thresholds for Caseness

The Hospital Anxiety and Depression Scale (HADS) employs subscale-specific thresholds to determine "caseness," defined as the probable presence of a mood disorder. According to the original developers, scores of 0–7 on either the anxiety (HADS-A) or depression (HADS-D) subscale are considered normal, 8–10 indicate borderline abnormal levels, and 11 or higher suggest probable caseness. These thresholds were established to identify clinically significant symptoms in medical settings without relying on somatic indicators that might confound results in physically ill patients. Scores are commonly further categorized in clinical use as 0–7 (normal), 8–10 (mild), 11–14 (moderate), and 15–21 (severe), though this elaboration reflects subsequent refinements rather than the original publication. A comprehensive supports the use of cutoffs around 8 for both subscales to balance against gold-standard diagnostic interviews such as the (SCID). For HADS-A, a threshold of ≥8 yields a of 0.90 and specificity of 0.78; for HADS-D, is 0.83 with specificity of 0.79. Recent meta-analyses indicate that for detecting major in physically ill patients, a HADS-D cutoff of ≥7 optimizes (0.82) and specificity (0.78). While a total HADS score of ≥11 can suggest significant overall distress, the subscales are preferred for interpretation to distinguish anxiety from , as the instrument was designed to measure these dimensions separately. In certain populations, such as the elderly, evidence suggests that lower thresholds may be needed compared to younger groups to account for age-related differences in symptom expression, though specific adjustments vary by study and context.

Clinical Decision-Making

In clinical practice, borderline scores of 8–10 or higher (≥11 for probable caseness) on either the anxiety or depression subscale of the Hospital Anxiety and Depression Scale (HADS) indicate the need for further , such as through a structured clinical or referral to services for comprehensive . This approach helps identify patients requiring more intensive psychiatric input while minimizing unnecessary referrals. The HADS serves as an effective monitoring tool, with repeat administrations allowing clinicians to track changes in anxiety and depression symptoms over time, such as before and after interventions. This repeated use facilitates of treatment response and adjustment of plans based on symptom trajectories. HADS scores are integrated with patients' clinical history and other relevant data to inform screening decisions, emphasizing its role in enhancing efficiency rather than providing a standalone . This approach ensures that elevated scores trigger targeted discussions and holistic evaluations without over-reliance on the scale alone. Clinical guidelines recommend the HADS for routine screening of anxiety and in cancer and settings, where it supports stepped care models by using subscale scores to determine the appropriate intensity of interventions, from low-level support to specialized therapy.

Psychometric Properties

Reliability

The Hospital Anxiety and Depression Scale (HADS) demonstrates strong , as measured by coefficients, which typically range from 0.80 to 0.90 for the anxiety subscale (HADS-A) and 0.75 to 0.85 for the subscale (HADS-D) in populations. A comprehensive review of 747 studies reported mean alphas of 0.83 for HADS-A (range 0.68–0.93) and 0.82 for HADS-D (range 0.67–0.90), supporting its reliability across diverse and community samples. Test-retest reliability of the HADS is also robust, with intraclass correlation coefficients (ICCs) generally ranging from 0.80 to 0.90 over intervals of 1–2 weeks in stable patient groups. Systematic evidence from chronic illness populations, such as those with stable chronic obstructive pulmonary disease, indicates moderate- to high-quality support for ICC values of 0.86–0.90 for both subscales, confirming score stability in non-acute settings. Similar findings hold in broader validation efforts, where short-term retest ICCs exceed 0.84 in outpatient cohorts. Concurrent validity with clinician ratings is high in validation samples, with agreement coefficients of 0.85 or greater. This level of concordance underscores the scale's utility as a self-administered tool that aligns well with professional assessments in clinical contexts. The HADS maintains consistent reliability across language translations, with Cronbach's alphas exceeding 0.70 for both subscales in versions such as and . For instance, the Spanish adaptation yields alphas of 0.86 for HADS-A and 0.86 for HADS-D, while the Chinese version shows 0.81 for HADS-A and 0.74 for HADS-D, though the depression subscale occasionally trends slightly lower in non-Western samples. These properties affirm the scale's cross-cultural applicability while highlighting minor variations in the depression domain.

Validity

The Hospital Anxiety and Depression Scale (HADS) demonstrates solid through moderate to strong correlations with established gold-standard measures of and (r ≈ 0.60–0.80), while minimizing overlap with somatic symptoms common in medical populations. Specifically, the HADS anxiety subscale correlates with the at coefficients ranging from 0.60 to 0.80, and the depression subscale shows correlations of 0.62 to 0.73 with the , reflecting its ability to capture psychological dimensions without confounding physical illness indicators. Concurrent validity is supported by meta-analytic evidence indicating that HADS subscales achieve sensitivity and specificity values of approximately 0.80 at a cutoff score of 8 or higher for detecting anxiety disorders and depression against structured clinical interviews. A 2021 meta-analysis in physically ill patients optimized the depression subscale cutoff at ≥7, yielding sensitivity of 0.82 and specificity of 0.78. Predictive validity has been evidenced in oncology settings, where baseline HADS scores effectively forecast anxiety and depression symptoms at 6-month follow-ups, aiding in the identification of patients at risk for poor treatment response and persistent distress. The HADS exhibits strong in distinguishing anxiety from , outperforming scales that include items in medically ill samples by focusing on affective and cognitive symptoms and avoiding somatic overlap common in conditions like . However, validity is reduced in certain subgroups, including patients with , where elevated psychological symptoms may lead to false positives for caseness due to overlapping distress mechanisms.

Factor Structure

The Hospital Anxiety and Depression Scale (HADS) was originally designed with a two-factor structure, distinguishing anxiety from based on item content, without initial empirical . Early (EFA) supported this intended bifactor model, identifying two correlated factors corresponding to anxiety and subscales, with eigenvalues greater than 1 using the Kaiser criterion in a sample of 568 cancer patients. Subsequent studies have proposed alternative models, including a three-factor structure identified through EFA, comprising autonomic anxiety (items reflecting physical symptoms of anxiety), anhedonic (items capturing loss of enjoyment), and positive (items indicating ). Meta-reviews have further evaluated bifactor models, incorporating a general distress factor alongside specific anxiety and group factors, which accounted for the majority of item variance (73%) and provided superior empirical support compared to unifactor or strictly two-factor solutions. Confirmatory factor analysis (CFA) of the two-factor model has yielded varying fit indices across studies, with comparative fit index (CFI) values often exceeding 0.90 in Western samples, indicating acceptable to good fit, though error of approximation (RMSEA) and standardized (SRMR) sometimes suggest room for improvement due to high inter-factor correlations (>0.70). In non-Western samples, such as those from or populations, CFA fit for the two-factor model tends to be poorer, with CFI below 0.90 and higher RMSEA (>0.08), potentially reflecting cultural differences in symptom expression or issues. These findings imply that the HADS primarily captures an underlying dimension of general psychological distress rather than distinctly separable anxiety and constructs, as evidenced by the dominance of the general factor in bifactor models. Ongoing research, including a 2023 study in patients, continues to support this interpretation.

Clinical Applications

Use in Medical Settings

Anxiety and Depression Scale (HADS) is routinely integrated into hospital and workflows to facilitate early detection of anxiety and depression among medically ill patients, serving as a brief, self-report that takes 2-5 minutes to complete. Designed specifically for non-psychiatric medical settings, it avoids symptoms that could confound physical illness, enabling its use alongside routine clinical assessments. In practice, HADS is administered during initial consultations or follow-ups, with scores guiding referrals to services and supporting shared decision-making between patients and providers. In , HADS is commonly employed for screening at the time of , identifying psychological distress in about 25.7% of new cancer patients upon their first appointment, which prompts timely counseling for over 80% of those exceeding thresholds. Within , particularly following , it effectively screens for with high (81% at a cut-off of ≥7), helping clinicians prioritize interventions in post-acute care phases. In , HADS supports early intervention protocols by monitoring mood changes, as demonstrated in trials where its use alongside standard oncologic care reduced depressive symptoms from 38% to 16% at 12 weeks. HADS is often embedded in electronic health records (EHRs) through patient portals, allowing digital completion and direct access for healthcare providers to review results during consultations; in advanced systems, elevated scores can trigger automated alerts to expedite follow-up. This integration enhances efficiency in busy environments. Regarding cost-effectiveness, HADS screening detects anxiety and depression in 20-30% of inpatients, such as 26.6% for anxiety and 28.6% for among cancer patients, enabling early interventions that reduce untreated cases and overall healthcare burdens. training for interpretation is brief and straightforward, requiring no specialized expertise beyond familiarizing with scoring thresholds (0-7 normal, 8-10 borderline, ≥11 probable disorder), which supports its widespread adoption.

Populations and Contexts

The Hospital Anxiety and Depression Scale (HADS) was originally developed for screening anxiety and depression among adult medical inpatients, primarily those aged 18 to 65 years in non-psychiatric hospital settings, where emotional distress often co-occurs with physical illness but symptoms are minimized to avoid . It has since been validated for use in elderly populations over 70 years, with studies examining potential threshold adjustments to better capture symptom expressions in older adults. Validation in adolescents is more limited, with evidence supporting its reliability and factor structure in this age group for distinguishing depressive and anxiety disorders, though adaptations are typically needed due to developmental differences in emotional reporting. In research contexts, HADS serves as a standardized in randomized controlled trials, such as those evaluating antidepressants, where it tracks changes in anxiety and symptoms over time. For community-based applications, it facilitates screening in settings to detect at-risk individuals early and guide referrals. Additionally, HADS has been integrated into protocols to remotely assess emotional distress in patients with limited access to in-person care. Among special populations, cancer patients frequently endorse high levels of anxiety and on HADS, reflecting the psychological impact of , , and . It is also commonly applied in chronic illnesses like (COPD), where it identifies comorbid emotional symptoms that exacerbate disease management. To address linguistic diversity, cultural adaptations of HADS have been developed for non-English speakers, including validated translations into for South Asian communities, Arabic for Middle Eastern populations, and for Southeast Asian users, ensuring cultural equivalence in item interpretation. HADS is generally excluded from use in individuals with severe , as the self-report format demands sufficient comprehension and , which may be compromised in conditions like advanced . Similarly, it is not suitable for patients experiencing active , where perceptual distortions and thought disorders can invalidate responses, aligning with its design for non-primary psychiatric populations.

Criticisms and Limitations

Methodological Concerns

One notable methodological concern with the Hospital Anxiety and Depression Scale (HADS) is the overemphasis on within its depression subscale (HADS-D), which primarily assesses loss of interest and enjoyment rather than the full spectrum of depressive symptoms. This focus limits the scale's , as it captures only four of the 13 core symptoms of according to diagnostic criteria, omitting key facets such as guilt, worthlessness, and suicidality. Consequently, HADS-D may reflect a narrow anhedonic subtype of influenced more by traits like low extraversion than by broader depressive pathology, potentially leading to under-detection of diverse presentations in clinical populations. The factor structure of the HADS has demonstrated instability across diverse studies, undermining its intended two-factor model of distinct anxiety and subscales. Confirmatory factor analyses frequently support a three-factor solution—involving autonomic anxiety, anhedonic , and a general factor—rather than the original bifactor design, with inconsistencies arising from ambiguous item wording and shifting response options. This lack of structural robustness has prompted calls to abandon the HADS altogether, as its poor discrimination between anxiety and (with as low as 0.56 for major ) renders it unreliable for precise diagnostic or screening purposes in non-psychiatric settings. Cultural biases inherent in the HADS's original formulation pose significant challenges for cross-cultural applicability, particularly through idiomatic expressions that resist accurate and . For instance, items referencing "" or feeling "wound up" employ colloquial phrasing unfamiliar or nonsensical in non- contexts, such as Omani or Nigerian , necessitating substantial adaptations like substituting "my breathing flying out of my stomach" for the former. These difficulties contribute to lower validity in Asian and samples, where inconsistent factor structures and reduced scores compared to norms suggest cultural insensitivity, with only a minority of validation studies adequately addressing across languages. Although designed as a brief tool, the HADS's 14 items can impose a response burden on acutely ill patients, potentially exacerbating or cognitive during completion. Questionnaire length is a known contributor to respondent burden in patient-reported outcomes, particularly among those with physical or mental exhaustion, where even short scales may reduce completion rates or accuracy. In hospital settings, this concern is amplified for individuals with acute conditions, as the scale's self-report assumes sufficient energy and concentration, which may not align with the realities of severe illness.

Recent Developments

A 2021 meta-analysis published in , drawing on data from over 25,000 participants across 101 studies, assessed the accuracy of the Hospital Anxiety and Depression Scale subscale (HADS-D) for screening major . At a cutoff score of ≥8, the pooled was 0.74 (95% 0.68-0.79) and specificity was 0.84 (95% 0.81-0.87) when using semi-structured diagnostic interviews, indicating moderate performance in identifying cases while minimizing false positives. The authors recommended integrating HADS-D with brief tools like the PHQ-2 to enhance overall screening efficiency, particularly in high-volume clinical environments. Ongoing debates in psychometric research emphasize the adoption of bifactor scoring approaches for the HADS to account for a general distress factor alongside specific anxiety and depression dimensions, improving analytical precision in contemporary studies. A 2023 study in Scientific Reports applied bifactor modeling to HADS data from 874 adults with traumatic brain injury, revealing a dominant general distress factor accounting for most variance, with specific subscales showing low reliability and limited ability to differentiate anxiety from depression; the total score was deemed more valid for assessing general distress. The emergence of digital applications for real-time HADS administration and scoring has gained traction, enabling automated feedback and integration into platforms for timely interventions. In light of accumulating evidence, several expert panels and guidelines since 2020 have advocated shifting primary reliance from the HADS to the for depression and GAD-7 for anxiety, citing their superior validation across large, diverse cohorts and alignment with criteria for more reliable case detection. For example, a 2021 comparative analysis highlighted the and GAD-7's higher correlations with gold-standard diagnoses in patients, underscoring their stronger evidence base for routine clinical use.

References

  1. [1]
  2. [2]
  3. [3]
    Accuracy of the Hospital Anxiety and Depression Scale ... - The BMJ
    May 10, 2021 · When screening for major depression, a HADS-D cut-off value of seven or higher maximised combined sensitivity and specificity.
  4. [4]
    Bifactor analysis of the Hospital Anxiety and Depression Scale ...
    May 17, 2023 · Anxiety and depression symptoms are commonly experienced after traumatic brain injury (TBI). However, studies validating measures of anxiety ...
  5. [5]
    The Hospital Anxiety and Depression Scale - Zigmond - 1983
    A self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital ...
  6. [6]
    The Hospital Anxiety And Depression Scale
    Aug 1, 2003 · Zigmond AS, Snaith RP: The Hospital Anxiety And Depression Scale. Acta Psychiatr Scand 1983, 67: 361–70. Article CAS PubMed Google Scholar.
  7. [7]
    Problems in Cross-Cultural Use of the Hospital Anxiety and ... - NIH
    Aug 9, 2013 · This article examines whether these problems could be due to the construction of the HADS that poses difficulties for translation and cross-cultural use.
  8. [8]
    The Hospital Anxiety And Depression Scale - PMC - PubMed Central
    Aug 1, 2003 · The 'anxiety' level was assessed by the questions: "Do you feel tense and wound up? Do you worry a lot? Do you have panic attacks? Do you feel ...
  9. [9]
    Hospital Anxiety and Depression Scale (HADS) - Stroke Engine
    The original HADS is available as an appendix in Zigmond and Snaith (1983). A copy of the article is available by clicking here. The HADS is also available ...In-Depth Review · Summary · Psychometric Properties
  10. [10]
    Hospital Anxiety and Depression Scale - Shirley Ryan AbilityLab
    Apr 26, 2012 · The Hospital Anxiety and Depression Scale is a two dimension scale ... Age Ranges. Adolescent. 13 - 17. years. Adult. 18 - 64. years. Elderly ...
  11. [11]
    [PDF] Hospital Anxiety and Depression Scale (HADS)
    your replies: your immediate reaction to each item will probably be more accurate than a long thought out response. I feel tense or 'wound up': A. I feel as ...
  12. [12]
    Clinimetrics: Hospital Anxiety and Depression Scale - ScienceDirect
    Summary. The Hospital Anxiety and Depression Scale (HADS) was developed to assess depression and anxiety in patients with illness and in the general population.
  13. [13]
    Detecting anxiety and depression among people with limited literacy ...
    May 7, 2021 · The hospital anxiety and depression scale (HADS) is one of the most commonly used measures for assessing emotional state because it is reported ...
  14. [14]
  15. [15]
    The hospital anxiety and depression scale - PubMed
    A self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital ...
  16. [16]
    The validity of the Hospital Anxiety and Depression Scale ... - PubMed
    In most studies an optimal balance between sensitivity and specificity was achieved when caseness was defined by a score of 8 or above on both HADS-A and HADS-D ...
  17. [17]
    Psychometric validation of the Hospital Anxiety and Depression ...
    Dec 5, 2023 · This study aimed to examine the psychometric properties of HADS in older adults 70 + living at home in a large Norwegian city.
  18. [18]
    Use of the Hospital Anxiety and Depression Scale (HADS) in a ... - NIH
    Every patient who presented a score greater than or equal to 8 in the “anxiety” or “depression” subscores of the HADS was referred to a psychiatrist at the ...
  19. [19]
    Test Performance Characteristics of the AIR, GAD-7, and HADS ...
    Aug 7, 2017 · Scores range from 0 to 21 for each subscale, with a score of 8 or more ... mental health specialist for appropriate diagnosis (further assessment) ...Missing: prompts | Show results with:prompts<|separator|>
  20. [20]
    'Worried to death': the assessment and management of anxiety ... - NIH
    Dec 11, 2017 · The most extensively validated screening tool in palliative care populations is the Hospital Anxiety and Depression Scale (HADS) [15–17].
  21. [21]
    Hospital Anxiety and Depression Scale (HADS): validation in ... - PMC
    The Hospital Anxiety and Depression Scale (HADS) was developed by Zigmond and Snaith [1] in 1983. Its purpose is to provide clinicians with an acceptable, ...
  22. [22]
    Stepped care targeting psychological distress in head and neck and ...
    May 10, 2012 · Only those patients, who do not recover, step up to a more intensive treatment. The HADS score is used to determine stepped-up levels of care.
  23. [23]
    Review The validity of the Hospital Anxiety and Depression Scale
    The Hospital Anxiety and Depression Scale (HADS) [1] was developed by Zigmond and Snaith in 1983 to identify caseness (possible and probable) of anxiety ...
  24. [24]
    Psychometric properties of the Hospital Anxiety and Depression ...
    Mar 2, 2023 · Moderate-quality evidence supported the test-retest reliability of the HADS-A and HADS-D with excellent coefficient values of 0.86-0.90.
  25. [25]
    Evaluation of the psychometric characteristics of the Spanish version ...
    The Spanish version of the HADS demonstrated good reliability and validity when used in medical patients.
  26. [26]
    Predicting anxiety and depression among cancer patients: a clinical ...
    The aim of this study was to investigate the possibility of predicting anxiety and depression 6 months after the cancer diagnosis.
  27. [27]
    Discriminant validity of the Hospital Anxiety and Depression Scale ...
    The objective of this study was to investigate the discriminant validity of commonly used depression and anxiety screening tools in order to determine the most ...
  28. [28]
    Reliability and validity of the Depression and Somatic Symptoms Scale
    Jan 14, 2019 · The HADS has been validated for use in patients with acute low back pain. ... pain easily lead to a false-positive or over-diagnosis of ...
  29. [29]
    The factor structure and factor stability of the hospital anxiety and ...
    An exploratory factor analysis of the HAD was carried out in 568 cancer patients. Two distinct, but correlated, factors emerged which corresponded to the ...
  30. [30]
    Factor structure of the Hospital Anxiety and Depression Scale in ...
    May 17, 2009 · The factor structure refined by exploratory factor analysis includes the error variance due to measurement error and a random component in ...
  31. [31]
    Feasibility of a Digital Patient–Provider Communication Intervention ...
    Anxiety and depression were measured with the Hospital Anxiety and Depression Scale (HADS) ... Remote symptom monitoring integrated into electronic health records ...
  32. [32]
    Screening new cancer patients for psychological distress ... - PubMed
    Screening new cancer patients for psychological distress using the hospital anxiety and depression scale. Psychooncology. 2007 Jun;16(6):534-42. doi: 10.1002 ...
  33. [33]
    Using the Hospital Anxiety and Depression Scale to screen for ...
    In particular, the HADS has been used extensively and effectively among patients following a myocardial infarction (MI) [20], [21], [24]. The HADS measures ...<|separator|>
  34. [34]
    Early Palliative Care for Patients with Metastatic Non–Small-Cell ...
    Aug 19, 2010 · Mood was assessed with the use of both the Hospital Anxiety and Depression Scale (HADS) and the Patient Health Questionnaire 9 (PHQ-9). The 14- ...
  35. [35]
    Design and evaluation of a digital health intervention ... - BMJ Open
    Symptom reporting will be linked to automated alerts ... Psychometric properties of the hospital anxiety and depression scale (HADS) in a Mexican population of ...
  36. [36]
    Intensity and Prevalence of Psychological Distress in Cancer ...
    This study used the Hospital Anxiety and Depression Scale (HADS) to assess the intensity and prevalence of psychological distress (ie, anxiety and depression) ...
  37. [37]
    Validation of the Hospital Anxiety and Depression Scale for use with ...
    The HADS has adequate test-retest reliability and factor structure, and discriminates between adolescents diagnosed with depressive or anxiety disorders and ...
  38. [38]
    Antidepressants in the treatment of depression ... - BMC Psychiatry
    May 16, 2013 · The Hospital Anxiety and Depression Scale (HADS) was administered for assessment of depression and anxiety during the study. Inclusion ...
  39. [39]
    Validity of the Hospital Anxiety and Depression Scale (HADS) in ...
    Conclusion: The HADS is a valid and reliable instrument for anxiety and depression screening in adult patients of primary healthcare services in Colombia.
  40. [40]
    The Effect of Telehealth Communication on Anxiety, Depression ...
    Mar 13, 2023 · The data in this study were collected using a demographic information form and the Hospital Anxiety and Depression Scale (HADS). The ...
  41. [41]
    Screening for depression and anxiety in cancer patients ... - PubMed
    Nine hundred and thirty inpatients and outpatients with cancer were approached to complete the Hospital Anxiety and Depression Scale (HADS).Missing: oncology | Show results with:oncology
  42. [42]
    The use of the Hospital Anxiety and Depression Scale (HADS) in ...
    Aims: To investigate the use of the Hospital Anxiety and Depression Scale (HADS) with recuperating chronic obstructive pulmonary disease (COPD) patients.
  43. [43]
    Cross-cultural adaptation into Punjabi of the English version of the ...
    The English version of the HADS was translated into the Punjabi language. ... Therefore, it is important to have such tools available in different languages ...
  44. [44]
    Testing of the Hospital Anxiety and Depression Scale in Patients ...
    This preliminary validation study supports the A-HADS as a reliable and valid instrument for the assessment of anxiety and depression in Arabic speaking ...
  45. [45]
    Validation of Hospital Anxiety and Depression Scale in an ...
    Jun 5, 2023 · This study aims to adapt the English-language Hospital Anxiety and Depression Scale (HADS) to the Indonesian language and evaluate the validity and reliability ...
  46. [46]
    Limited validity of the Hospital Anxiety and Depression Scale (HADS ...
    Aug 5, 2025 · HADS is not a suitable tool for the assessment of anxiety and depression in patients with mild and moderate cognitive impairment [23] . Edmonton ...
  47. [47]
  48. [48]
  49. [49]
  50. [50]
    Response burden and questionnaire length: is shorter ... - PubMed
    A factor that has been proposed to affect the response burden is questionnaire length, and this burden is manifested in, for example, response rate. Even ...Missing: HADS | Show results with:HADS
  51. [51]
    Examining the optimal cutoff values of HADS, PHQ‐9 and GAD‐7 as ...
    May 3, 2021 · Scores were defined as: ≥5 mild, ≥10 moderate, and ≥15 severe anxiety. The recommended screening cutoff was ≥10, corresponding with at least a ...